Bolsas y Mercados Españoles
Company
search
PHARMA MAR, S.A.
AddressAV/ DE LOS REYES 1, 28770 COLMENAR VIEJO-MADRID 
Listed Capital11,132,464.20 Euros



PHARMA MAR
ISINES0169501022 TickerPHM Nominal0.60 MarketContinuous Market Admitted Capital11,132,464.20 Euros 

Last prices
DateHourCloseRef.% Dif.LastHighLowAvg.VolumeTurnover
25/09/2020Close102.400098.95003.49102.4000102.400097.6500100.1745121,25812,147,041.00
X
25/09/2020 17:37:05
BidAsk
OrdersVolumePricePriceVolumeOrders
111102.4000102.50002,05412
4162102.3000102.60009077
3240102.2000102.70007635
3271102.1000102.80007667
4398102.0000102.90005934

Last pay
TypeEx-datePayment DateConcept
Dividend26/06/202030/06/2020Annual 2019

Last split
DateEquivalence
 

Last reverse split
DateEquivalence
22/07/20201 x 12

Last capital increase
PeriodProportionType
02/06/20172 x 1,000Premium


 2020
until 25/09
2019201820172016
Capitalisation *
(thousands of euros)
1,899,941794,858242,688552,170602,175
Shares
(x 1,000)
18,554222,649222,649222,649222,205
Period Close Price
(euros)
102.400042.840013.080029.760032.5200
Period Last Price
(euros)
102.400042.840013.080029.760032.5200
Period High Price
(euros)
138.600046.152033.144051.060038.3400
Period Low Price
(euros)
30.000012.936010.452024.420020.2800
Volume
(thousands of shares)
45,92926,78618,45717,10711,821
Turnover
(thousands of euros)
3,233,712650,774348,611654,106354,012

Profile

Headquartered in Madrid, PharmaMar is a world-leading biopharmaceutical company in the discovery and development of innovative marine-derived anticancer drugs. The company has an important pipeline of drug candidates and a robust R&D oncology program.

PharmaMar develops and commercializes YONDELIS® in Europe and has three clinical-stage programs under development for several types of solid and hematological cancers, PM1183, plitidepsin, and PM60184. PharmaMar is a global biopharmaceutical company with subsidiaries in Germany, Italy, France, Switzerland, United Kingdom and the United States.

PharmaMar fully owns other companies: GENOMICA, Spain's leading molecular diagnostics company; Sylentis, dedicated to researching therapeutic applications of gene silencing (RNAi); and two other chemical enterprises, Zelnova and Xylazel.

To learn more about PharmaMar, please visit us at www.pharmamar.com.

 

Source: Issuing company.
26/09/2020 00:02:01

Research

To obtain detailed information or information in other formats, please contact BME Market Data at marketdata@grupobme.es or visit the website www.bmemarketdata.es.

The information provided by the different websites of Grupo BME is for internal use only. For any commercial use and/or other usage that involves the redistribution of the information to third parties, it is required a prior and express permission from BME Market Data. Please contact us at marketdata@grupobme.es.

Follow us in:
Copyright © BME 2020